Pricing Log in Create free account
Saturday 17 October 2026 Export OSUR’s income statement to Excel — free account

OraSure Technologies, Inc.

OSUR Healthcare Medical Instruments & Supplies

OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024. In the quarter to June 2026, revenue fell 1.93%, EPS grew 134.6%, free cash flow fell 1.40% and total debt fell 8.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.61 0.20 −5.25%
Market cap
$262.8M
P/E
0.0×
Fwd P/E
−3.9×
Dividend yield
—
F-score
3/9
Altman Z
1.47
Beneish M
−2.73
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.55
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — 4 — 1 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 6.66%

Capital & Financial Ratios $m

Market Cap 262.77
Revenue 112.41
Net Income (49.13)
Free Cash Flow (48.83)
Net Debt (160.46)
Current Ratio 8.88 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.85) (negative: loss-making)
P/S ratio 2.22
P/B ratio 0.78
Past 5Y EPS Growth —
This Y EPS Growth 29.79% (at or above 15%: strong)
Next Y EPS Growth (22.73%) (below 0%: weak)
Next Y revenue growth 6.15%
Next 5Y EPS Growth (27.98%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 2.1×; over the ten years it ranged from −0.3× in 2025 to 8.2× in 2017.
P/S against its own 10 years 39.40%
10-year low 10-year high
P/B against its own 10 years 20.20%
10-year low 10-year high
EV/Sales against its own 10 years 29.24%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 290 268 199 161
Receivables 40 24 22 27
Inventory 48 34 31 30
Other 2 3 4 2
386 333 262 223
2023 2024 2025 Q'26
Payables 13 8 7 8
ST’ Debt — — — —
Other 25 22 18 16
40 33 40 25

Compound Annual Growth %

10y 5y 3y
Sales (0.40%) (7.70%) (33.29%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 7.89% (3.08%) (2.21%)

Revenue $m

Mar Jun Sep Dec Year
’26 28 31 — — —
’25 30 31 27 27 115
’24 54 54 40 37 186
’23 155 85 89 76 405
’22 68 80 116 123 387
’21 59 58 54 64 234
’20 32 29 48 63 172
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (14) (10) — — —
’25 (20) (10) (10) (9) (49)
’24 7 8 13 0 27
’23 6 57 37 41 142
’22 (36) (10) 16 (18) (47)
’21 (4) 1 (19) (13) (35)
’20 2 (5) 4 4 6
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (12) — — —
’25 (19) (12) (11) (11) (53)
’24 5 6 13 0 24
’23 5 52 35 40 131
’22 (84) (21) 9 (15) (111)
’21 (15) (11) (24) (33) (83)
’20 0 (8) (1) (12) (23)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.32) 0.09 — — —
’25 (0.21) (0.26) (0.19) (0.27) (0.94)
’24 (0.05) (0.01) (0.06) (0.14) (0.26)
’23 0.37 (0.07) 0.15 0.27 0.72
’22 (0.28) (0.26) 0.07 0.21 (0.25)
’21 0.05 (0.02) (0.21) (0.14) (0.32)
’20 (0.12) (0.16) 0.01 0.03 (0.22)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 5.09 8.39 10.27 6.35 5.23 8.25 2.62 4.38 3.52 2.08

Analyst estimates 2026–2028

Powerpack
High 9.53 23.01 22.22 13.25 19.75 15.94 9.42 8.43 8.45 4.22
People
People Employees 325 377 398 472 570 785 840 638 501 500
Revenue/emp, $m 0.39 0.44 0.46 0.33 0.30 0.30 0.46 0.64 0.37 0.23
Income, $m
Income, $m Revenue 128 167 182 155 172 234 387 405 186 115
Gross margin, % 68.66 59.23 62.51 61.18 59.32 50.33 38.31 42.33 42.72 41.90
EBT 20 41 32 21 (4) (9) (16) 56 (16) (65)
EBT margin, % 15.85 24.56 17.45 13.80 (2.05) (3.98) (4.05) 13.87 (8.61) (56.15)
Net income 20 31 20 17 (15) (23) (17) 54 (19) (69)
Depreciation 6 6 6 7 9 12 15 21 11 10
Per share, $
Per share, $ Revenue 2.31 2.83 2.97 2.51 2.54 3.25 5.34 5.53 2.50 1.57
Earnings 0.35 0.52 0.33 0.27 (0.22) (0.32) (0.25) 0.73 (0.26) (0.94)
Cash flow 0.44 0.48 0.64 0.16 0.09 (0.49) (0.65) 1.93 0.37 (0.67)
Capex (0.08) (0.07) (0.10) (0.15) (0.43) (0.67) (0.88) (0.14) (0.05) (0.06)
Free cash flow 0.36 0.40 0.54 0.01 (0.34) (1.16) (1.53) 1.79 0.32 (0.72)
Book value 3.34 4.37 4.64 4.98 5.90 5.29 5.03 5.87 5.51 4.64
Shares, m 56 59 61 62 68 72 73 73 74 73
Valuation, ×
Valuation, × P/E 25.11 36.40 34.35 29.74 0.00 0.00 0.00 11.50 0.00 0.00
P/S 3.81 6.82 3.93 3.20 4.16 2.68 0.90 1.50 1.45 1.55
P/B 2.63 4.41 2.52 1.61 1.79 1.64 0.95 1.41 0.65 0.52
EV/Sales 2.87 5.89 3.07 2.20 2.95 2.03 0.61 0.78 0.01 (0.19)
EV/FCF 18.17 41.28 17.02 694.46 (24.27) (5.68) (2.13) 2.42 0.04 0.40
Cash, $m
Cash, $m Operating cash flow 25 28 39 10 6 (35) (47) 142 27 (49)
Capex (4) (4) (6) (9) (29) (48) (64) (10) (4) (4)
Free cash flow 20 24 33 0 (23) (83) (111) 131 24 (53)
Balance, $m
Balance, $m Working capital 139 190 191 192 242 231 256 347 300 222
Total debt — — — 1 1 2 1 0 0 0
Net debt (121) (156) (157) (155) (209) (151) (110) (290) (268) (199)
Shareholders’ equity 186 258 283 307 399 381 364 431 410 341
Returns, %
Returns, % ROA 9.93 12.28 6.67 5.01 (3.71) (5.02) (3.79) 11.58 (4.05) (15.57)
ROIC 19.52 24.61 14.01 7.64 (1.70) (2.77) (5.45) 14.54 (12.37) (31.75)
ROE 11.42 13.94 7.53 5.64 (4.23) (5.90) (4.60) 13.50 (4.64) (18.30)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

OraSure Technologies, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ANGO AngioDynamics, Inc. $487.0M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
NNNN Anbio Biotechnology $474.8M — — — — — — — Compare
EMBC Embecta Corp. $365.5M 4.2× 3.8× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
ZJYL Jin Medical International Ltd. $340.9M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
SMTI Sanara MedTech Inc. $322.4M — (loss-making) 125× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $262.8M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76%
UTMD Utah Medical Products, Inc. $237.8M 22.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $194.1M 13.8× 23.5× +16.65% (above 0%: growing) +143.24% (above 0%: growing) −78.95% (below 0%: shrinking) 34.75% 17.29% Compare
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21% Compare
Median of peers $331.7M 13.8× 26.1× +7.96% −10.64% −49.63% 56.42% 6.33%

All 55 Medical Instruments & Supplies stocks →

OraSure Technologies, Inc. (OSUR) key facts

  • Concern: OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024.
  • OraSure Technologies, Inc. (OSUR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, OSUR traded at $3.61, a market capitalization of $262.8 million.
  • Return on equity was −18.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.47 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

OraSure Technologies, Inc. (OSUR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/OSUR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com